| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -75,850 | -45,573 |
| Stock-based compensation expense | 20,125 | 9,960 |
| Non-cash interest expense | - | 0 |
| Net accretion of premiums and discounts on marketable securities | 4,340 | 3,300 |
| Non-cash lease expense | 319 | 187 |
| Depreciation expense | 55 | 35 |
| Prepaid expenses and other current assets | 3,167 | 765 |
| Subscription receivable | - | 0 |
| Other non-current assets | 60 | 60 |
| Accrued interest payable, related party | - | 0 |
| Accounts payable | -1,254 | 1,202 |
| Accrued expenses and other current liabilities | 5,038 | 232 |
| Operating lease liability | -468 | -29 |
| Related party accounts payable and other current liabilities | -6,014 | -5,903 |
| Net cash used in operating activities | -65,616 | -44,014 |
| Purchases of property and equipment | 146 | 47 |
| Purchases of marketable securities | 419,972 | 152,289 |
| Proceeds from maturities of marketable securities | 345,395 | 200,062 |
| Net cash used in investing activities | -74,723 | 47,726 |
| Proceeds from issuance of notes payable to related party, net of issuance costs paid | - | 0 |
| Proceeds from issuance of pre-merger oruka series a preferred stock, net of issuance costs paid | - | 0 |
| Proceeds from the pipe financings, net | 169,908 | - |
| Proceeds from issuance of common stock | 109 | 109 |
| Payment of deferred offering costs | - | 0 |
| Net cash provided by financing activities | 170,017 | 109 |
| Net increase in cash and cash equivalents | 29,678 | 3,821 |
| Cash and cash equivalents at beginning of period | 61,575 | - |
| Cash and cash equivalents at end of period | 91,253 | - |
Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA)